NeuroKaire

Company Overview

Snapshot

Founded in August 2018 by Talia Cohen Solal and Daphna Laifenfeld, NeuroKaire operates with 11–50 employees. The company has raised a total of $26.27M across 8 funding rounds from 7 investors. In September 2025, NeuroKaire launched the world’s first blood test designed to personalize depression treatment, marking a significant advancement in precision medicine for psychiatry.

Business overview

NeuroKaire, formerly Genetika+, is a Health Tech & Life Sciences company focused on developing personalized medical testing tools for psychiatry and neurology. The company's core technology involves an AI-powered platform that predicts optimal drug treatments for patients, particularly those suffering from depression. By enabling faster treatment, reducing side effects, and optimizing dosing, NeuroKaire aims to improve patient outcomes. It operates in the Digital Healthcare sector, specifically within Digital Medical Diagnostics and Medical Decision Support, serving clinicians, biopharma companies, and patients in the United States and Europe.

Strategic signal

In September 2025, NeuroKaire launched the world's first blood test for personalized depression treatment. This development is significant as it addresses a critical need for more effective and tailored mental health interventions, potentially reducing the trial-and-error approach often associated with antidepressant prescriptions. For investors, this signals a strong market entry with a novel diagnostic tool, positioning NeuroKaire as a leader in precision medicine for psychiatric care and indicating potential for rapid commercialization and adoption in the healthcare industry.

Company Intelligence Q&A

What is NeuroKaire's primary focus in precision medicine?

NeuroKaire specializes in precision medicine for psychiatry and neurology, developing medical testing tools to personalize drug therapy for conditions like depression, aiming to optimize treatment selection, minimize side effects, and improve patient outcomes.

When did NeuroKaire launch its personalized depression treatment blood test?

In September 2025, NeuroKaire launched the world’s first blood test designed to personalize depression treatment.

Which organizations provided non-equity funding to NeuroKaire in May 2026?

In May 2026, NeuroKaire received non-equity funding from the BIRD Foundation as part of new U.S.-Israel projects.

What significant regulatory milestone did Genetika+ achieve in October 2022?

In October 2022, Genetika+ obtained the CE-IVD mark for its NeuroKaire blood test, an AI-powered tool designed to optimize depression treatment.

Which investors participated in NeuroKaire's funding round in June 2024?

In June 2024, NeuroKaire secured funding from investors including GreyBird Ventures.